Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Clovis Oncology, Inc. (CLVSQ) had Revenue of $148.76M for the most recently reported fiscal year, ending 2021-12-31.

Quarterly Annual

Figures for fiscal year ending 2021-12-31

Income Statement Financials
Revenue	$148.76M
Net Income	$-264.52M
Cost of Goods Sold	$38.83M
Gross Profit	$109.93M
Operating Expenses	$374.52M
Operating Income	$-225.77M
Non-Operating Income/Expense	$-39.16M
Pre-Tax Income	$-264.93M
Normalized Pre-Tax Income	$-264.93M
Income after Taxes	$-264.52M
Income from Continuous Operations	$-264.52M
Consolidated Net Income/Loss	$-264.52M
Normalized Income after Taxes	$-264.52M
EBIT	$-225.77M
EBITDA	$-214.84M
Weighted-Average Shares Outstanding (Basic)	115.53M
Weighted-Average Shares Outstanding (Diluted)	115.53M
Earnings per Share (EPS) (Basic)	$-2.29
Earnings per Share (EPS) (Diluted)	$-2.29
Balance Sheet Financials
Current Assets	$198.09M
Property, Plant, and Equipment	$6.55M
Long-Term Assets	$274.75M
Total Assets	$472.83M
Current Liabilities	$125.21M
Long-Term Debt	$606.73M
Long-Term Liabilities	$626.46M
Total Liabilities	$751.67M
Common Equity	$-278.84M
Tangible Shareholders Equity	$-402.29M
Shareholders Equity	$-278.84M
Common Shares Outstanding	129.11M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-196.06M
Cash Flow from Investing Activities	$-0.31M
Cash Flow from Financial Activities	$100.16M
Beginning Cash	$240.23M
End Cash	$143.43M
Increase/Decrease in Cash	$-96.80M
Stock-Based Compensation	$25.45M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.58
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	1.85
Debt to Equity Ratio	-2.18
Gross Margin	73.90%
Operating Margin	-151.77%
EBIT Margin	-151.77%
EBITDA Margin	-144.42%
Pre-Tax Profit Margin	-178.09%
Profit Margin	-177.82%
Free Cash Flow	$-196.37M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.31
Inventory Turnover	2.84
Receiveable Turnover	5.54
Days Sales in Receivables	65.93
Return on Equity	94.87%
Return on Tangible Equity	65.76%
Return on Assets	-55.94%
Return on Investments	-80.68%
Book Value Per Share	$-2.16
Free Cash Flow per Share	$-1.70
Operating Cash Flow per Share	$-1.70

Data from Zacks Investment Research, Inc.